Vitasang develops novel diagnosis and blood rejuvenation products for blood management. Their portfolio includes Rejuvesol, the only FDA-approved blood rejuvenation product. The company is also developing a unique point-of-care rejuvenation device.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Stored red blood cells (RBCs) undergo changes known as "storage lesions," which impair their ability to deliver oxygen and facilitate blood flow, leading to harmful waste product generation and increased patient morbidity. Currently, no available solutions can reverse these storage-related degradations and extend the shelf life of stored blood.
Solution
Vitasang provides Rejuvesol, an FDA-approved technology designed to rejuvenate stored RBCs, improving their functionality and quality after the development of storage lesions. Rejuvesol restores levels of 2,3-DPG and ATP in stored RBCs to levels comparable to or exceeding those found in fresh blood, enhancing the cells' capacity to offload oxygen and traverse small vascular structures. Studies have demonstrated that Rejuvesol can reduce hospital stays by 15%, decrease infection rates by 30%, and lower RBC utilization by 25% in cardiac and orthopedic surgeries when compared to using blood stored for over 10 days. The technology aims to improve patient outcomes by enhancing the quality and effectiveness of transfused blood.
Target Audience
The primary customers are hospitals, blood banks, and military organizations seeking to improve the quality and extend the usability of stored red blood cells for transfusions.
Features
- Rejuvesol restores 2,3-DPG and ATP levels in stored red blood cells to levels found in fresh blood.
- The technology is FDA-approved for blood rejuvenation.
- Rejuvesol is designed to improve the ability of RBCs to offload oxygen and traverse through small vascular structures.
- The company is developing a point-of-care device for blood rejuvenation.